173 related articles for article (PubMed ID: 14534519)
1. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation.
Palovaara S; Pelkonen O; Uusitalo J; Lundgren S; Laine K
Clin Pharmacol Ther; 2003 Oct; 74(4):326-33. PubMed ID: 14534519
[TBL] [Abstract][Full Text] [Related]
2. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.
Turpeinen M; Tolonen A; Uusitalo J; Jalonen J; Pelkonen O; Laine K
Clin Pharmacol Ther; 2005 Jun; 77(6):553-9. PubMed ID: 15961986
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity.
Loboz KK; Gross AS; Williams KM; Liauw WS; Day RO; Blievernicht JK; Zanger UM; McLachlan AJ
Clin Pharmacol Ther; 2006 Jul; 80(1):75-84. PubMed ID: 16815319
[TBL] [Abstract][Full Text] [Related]
4. Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity.
Kharasch ED; Mitchell D; Coles R
J Clin Pharmacol; 2008 Apr; 48(4):464-74. PubMed ID: 18287571
[TBL] [Abstract][Full Text] [Related]
5. Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation.
Fan L; Wang JC; Jiang F; Tan ZR; Chen Y; Li Q; Zhang W; Wang G; Lei HP; Hu DL; Wang D; Zhou HH
Eur J Clin Pharmacol; 2009 Apr; 65(4):403-9. PubMed ID: 19066872
[TBL] [Abstract][Full Text] [Related]
6. The interaction between St John's wort and an oral contraceptive.
Hall SD; Wang Z; Huang SM; Hamman MA; Vasavada N; Adigun AQ; Hilligoss JK; Miller M; Gorski JC
Clin Pharmacol Ther; 2003 Dec; 74(6):525-35. PubMed ID: 14663455
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols.
Lau AJ; Chang TK
Drug Metab Dispos; 2009 Sep; 37(9):1931-7. PubMed ID: 19487249
[TBL] [Abstract][Full Text] [Related]
8. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects.
Robertson SM; Maldarelli F; Natarajan V; Formentini E; Alfaro RM; Penzak SR
J Acquir Immune Defic Syndr; 2008 Dec; 49(5):513-9. PubMed ID: 18989234
[TBL] [Abstract][Full Text] [Related]
9. The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel.
Korhonen T; Tolonen A; Uusitalo J; Lundgren S; Jalonen J; Laine K
Br J Clin Pharmacol; 2005 Jul; 60(1):69-75. PubMed ID: 15963096
[TBL] [Abstract][Full Text] [Related]
10. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.
Kirchheiner J; Klein C; Meineke I; Sasse J; Zanger UM; Mürdter TE; Roots I; Brockmöller J
Pharmacogenetics; 2003 Oct; 13(10):619-26. PubMed ID: 14515060
[TBL] [Abstract][Full Text] [Related]
11. Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects.
Kim H; Bae SK; Park SJ; Shim EJ; Kim HS; Shon JH; Liu KH; Shin JG
Br J Clin Pharmacol; 2010 Jul; 70(1):126-31. PubMed ID: 20642555
[TBL] [Abstract][Full Text] [Related]
12. Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy.
Laine K; Palovaara S; Tapanainen P; Manninen P
Clin Pharmacol Ther; 1999 Dec; 66(6):602-8. PubMed ID: 10613616
[TBL] [Abstract][Full Text] [Related]
13. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.
Barditch-Crovo P; Trapnell CB; Ette E; Zacur HA; Coresh J; Rocco LE; Hendrix CW; Flexner C
Clin Pharmacol Ther; 1999 Apr; 65(4):428-38. PubMed ID: 10223781
[TBL] [Abstract][Full Text] [Related]
14. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
Jefferson JW; Pradko JF; Muir KT
Clin Ther; 2005 Nov; 27(11):1685-95. PubMed ID: 16368442
[TBL] [Abstract][Full Text] [Related]
15. Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers.
Lei HP; Yu XY; Xie HT; Li HH; Fan L; Dai LL; Chen Y; Zhou HH
Xenobiotica; 2010 Apr; 40(4):275-81. PubMed ID: 20102294
[TBL] [Abstract][Full Text] [Related]
16. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
Hesse LM; Venkatakrishnan K; Court MH; von Moltke LL; Duan SX; Shader RI; Greenblatt DJ
Drug Metab Dispos; 2000 Oct; 28(10):1176-83. PubMed ID: 10997936
[TBL] [Abstract][Full Text] [Related]
17. Drug interaction study between bupropion and ticlopidine in male CF-1 mice.
Molnari JC; Hassan HE; Moeller BM; Myers AL
Biol Pharm Bull; 2011; 34(3):447-51. PubMed ID: 21372402
[TBL] [Abstract][Full Text] [Related]
18. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects.
Hogeland GW; Swindells S; McNabb JC; Kashuba AD; Yee GC; Lindley CM
Clin Pharmacol Ther; 2007 Jan; 81(1):69-75. PubMed ID: 17186001
[TBL] [Abstract][Full Text] [Related]
19. Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites.
Turpeinen M; Koivuviita N; Tolonen A; Reponen P; Lundgren S; Miettunen J; Metsärinne K; Rane A; Pelkonen O; Laine K
Br J Clin Pharmacol; 2007 Aug; 64(2):165-73. PubMed ID: 17335546
[TBL] [Abstract][Full Text] [Related]
20. Effects of sertraline on the pharmacokinetics of bupropion and its major metabolite, hydroxybupropion, in mice.
Molnari JC; Hassan HE; Myers AL
Eur J Drug Metab Pharmacokinet; 2012 Mar; 37(1):57-63. PubMed ID: 21928040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
